Catalent Pharma Solutions received notice that the FDA has approved the sale of a prescription product manufactured at its recently opened pre-filled syringe facility in Brussels, Belgium. Syringes from the Brussels facility will likely be dispensed to patients in the U.S. during the next few months.
   
Richard Yarwood, group president of Catalent’s Sterile Technologies segment, said, “We are very pleased to have reached this important milestone in the evolution of our Brussels facility, and to further extend our strategic partnership with this customer. With this first FDA product approval, we are even more strongly positioned to help our customers satisfy the fast growing U.S. market demand for drugs and biologics in the prefilled syringe format.”